Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B McInnes

Showing results (231-240 of 537) with videos related to

Pageof 54
Sort By:
Annals of the Rheumatic Diseases|April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.
Rheumatology and Therapy|March 15, 2024
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect ComparisonRichard B Warren, Iain B McInnes, Peter Nash, et al.
Rheumatology and Therapy|March 6, 2024
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Journal of the American Society of Nephrology : JASN|September 20, 2002
Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injuryTakaharu Tanaka, Takashi Kuroiwa, Hidekazu Ikeuchi, et al.
RMD Open|May 20, 2021
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trialsKristen Sweet, Qingxuan Song, Matthew J Loza, et al.
Annals of the Rheumatic Diseases|January 24, 2018
Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritisCatriona T Prendergast, Agapitos Patakas, Shaima Al-Khabouri, et al.
Arthritis Care & Research|May 14, 2013
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trialArthur Kavanaugh, Iain B McInnes, Gerald G Krueger, et al.
Rheumatology and Therapy|August 9, 2024
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Annals of the Rheumatic Diseases|July 30, 2011
A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cellsMichele Bombardieri, Ngar-Woon Kam, Fabia Brentano, et al.
Arthritis and Rheumatism|April 21, 2011
Characterization of the anticollagen antibody response in a new model of chronic polyarthritisPaola Conigliaro, Robert A Benson, Agapitos Patakas, et al.
Pageof 54

Showing results (231-240 of 537) with videos related to

Sort By:
Pageof 54
Annals of the Rheumatic Diseases|April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.
Rheumatology and Therapy|March 15, 2024
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect ComparisonRichard B Warren, Iain B McInnes, Peter Nash, et al.
Rheumatology and Therapy|March 6, 2024
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Journal of the American Society of Nephrology : JASN|September 20, 2002
Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injuryTakaharu Tanaka, Takashi Kuroiwa, Hidekazu Ikeuchi, et al.
RMD Open|May 20, 2021
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trialsKristen Sweet, Qingxuan Song, Matthew J Loza, et al.
Annals of the Rheumatic Diseases|January 24, 2018
Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritisCatriona T Prendergast, Agapitos Patakas, Shaima Al-Khabouri, et al.
Arthritis Care & Research|May 14, 2013
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trialArthur Kavanaugh, Iain B McInnes, Gerald G Krueger, et al.
Rheumatology and Therapy|August 9, 2024
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Annals of the Rheumatic Diseases|July 30, 2011
A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cellsMichele Bombardieri, Ngar-Woon Kam, Fabia Brentano, et al.
Arthritis and Rheumatism|April 21, 2011
Characterization of the anticollagen antibody response in a new model of chronic polyarthritisPaola Conigliaro, Robert A Benson, Agapitos Patakas, et al.
Pageof 54